Beneficial effects of 5-fluorouracil and heparin-based portal infusion chemotherapy combined with mitomycin c and cisplatin after curative resection of pancreatic cancer

Koichi Aiura, Shin Takahashi, Junichi Matsui, Masakazu Ueda, Yuukou Kitagawa

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Aims: We retrospectively assessed the benefits of 5-fluorouracil (5-FU)- and heparin-based portal infusion chemotherapy combined with systemic administration of mitomycin C (MMC) and cisplatin (CDDP) for 4 weeks following surgery (PI4W). The goal was to determine if this treatment prevented liver metastasis and improved survival for patients with potentially curative resection of pancreatic cancer. Methods: 68 patients who underwent pancreatectomy from January 1995 to August 2007 were treated. Of these cases, 22 patients received portal infusion with 5-FU (250 mg/day) for 2 weeks (PI2W) following surgery, while 25 patients received PI4W therapy (250 mg/day of 5-FU with 2,000 IU/day of heparin everyday for 4 weeks, 4 mg MMC on days 6, 13, 20, 27, and 10 mg CDDP on days 7, 14, 21, 28). The remaining 21 patients were treated without adjuvant therapy during the perioperative period. Results: All patients except one completed the portal infusion chemotherapy without toxicity. The cumulative liver metastasis-free survival rate in the PI4W group was significantly higher than those in the other two groups. Furthermore, in the PI4W group, 3-year survival was 91.6% and 5-year survival was 70.5%, rates which were significantly better than those observed in the other two groups. Conclusion: PI4W therapy after surgery is feasible and could become a promising adjuvant therapy in patients with potentially curative resection of pancreatic cancer.

Original languageEnglish
Pages (from-to)250-258
Number of pages9
JournalPancreatology
Volume10
Issue number2-3
DOIs
Publication statusPublished - 2010 Jun

Fingerprint

Mitomycin
Pancreatic Neoplasms
Fluorouracil
Cisplatin
Heparin
Drug Therapy
Survival
Neoplasm Metastasis
Therapeutics
Perioperative Period
Pancreatectomy
Liver
Survival Rate

Keywords

  • 5-Fluorouracil
  • Adjuvant therapy
  • Cisplatin
  • Curative resection, pancreatic cancer
  • Heparin-based portal infusion chemotherapy
  • Mitomycin C

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Medicine(all)

Cite this

Beneficial effects of 5-fluorouracil and heparin-based portal infusion chemotherapy combined with mitomycin c and cisplatin after curative resection of pancreatic cancer. / Aiura, Koichi; Takahashi, Shin; Matsui, Junichi; Ueda, Masakazu; Kitagawa, Yuukou.

In: Pancreatology, Vol. 10, No. 2-3, 06.2010, p. 250-258.

Research output: Contribution to journalArticle

@article{1f9368f4a41d4c9ca78ae2fc48f7a658,
title = "Beneficial effects of 5-fluorouracil and heparin-based portal infusion chemotherapy combined with mitomycin c and cisplatin after curative resection of pancreatic cancer",
abstract = "Aims: We retrospectively assessed the benefits of 5-fluorouracil (5-FU)- and heparin-based portal infusion chemotherapy combined with systemic administration of mitomycin C (MMC) and cisplatin (CDDP) for 4 weeks following surgery (PI4W). The goal was to determine if this treatment prevented liver metastasis and improved survival for patients with potentially curative resection of pancreatic cancer. Methods: 68 patients who underwent pancreatectomy from January 1995 to August 2007 were treated. Of these cases, 22 patients received portal infusion with 5-FU (250 mg/day) for 2 weeks (PI2W) following surgery, while 25 patients received PI4W therapy (250 mg/day of 5-FU with 2,000 IU/day of heparin everyday for 4 weeks, 4 mg MMC on days 6, 13, 20, 27, and 10 mg CDDP on days 7, 14, 21, 28). The remaining 21 patients were treated without adjuvant therapy during the perioperative period. Results: All patients except one completed the portal infusion chemotherapy without toxicity. The cumulative liver metastasis-free survival rate in the PI4W group was significantly higher than those in the other two groups. Furthermore, in the PI4W group, 3-year survival was 91.6{\%} and 5-year survival was 70.5{\%}, rates which were significantly better than those observed in the other two groups. Conclusion: PI4W therapy after surgery is feasible and could become a promising adjuvant therapy in patients with potentially curative resection of pancreatic cancer.",
keywords = "5-Fluorouracil, Adjuvant therapy, Cisplatin, Curative resection, pancreatic cancer, Heparin-based portal infusion chemotherapy, Mitomycin C",
author = "Koichi Aiura and Shin Takahashi and Junichi Matsui and Masakazu Ueda and Yuukou Kitagawa",
year = "2010",
month = "6",
doi = "10.1159/000244265",
language = "English",
volume = "10",
pages = "250--258",
journal = "Pancreatology",
issn = "1424-3903",
publisher = "S. Karger AG",
number = "2-3",

}

TY - JOUR

T1 - Beneficial effects of 5-fluorouracil and heparin-based portal infusion chemotherapy combined with mitomycin c and cisplatin after curative resection of pancreatic cancer

AU - Aiura, Koichi

AU - Takahashi, Shin

AU - Matsui, Junichi

AU - Ueda, Masakazu

AU - Kitagawa, Yuukou

PY - 2010/6

Y1 - 2010/6

N2 - Aims: We retrospectively assessed the benefits of 5-fluorouracil (5-FU)- and heparin-based portal infusion chemotherapy combined with systemic administration of mitomycin C (MMC) and cisplatin (CDDP) for 4 weeks following surgery (PI4W). The goal was to determine if this treatment prevented liver metastasis and improved survival for patients with potentially curative resection of pancreatic cancer. Methods: 68 patients who underwent pancreatectomy from January 1995 to August 2007 were treated. Of these cases, 22 patients received portal infusion with 5-FU (250 mg/day) for 2 weeks (PI2W) following surgery, while 25 patients received PI4W therapy (250 mg/day of 5-FU with 2,000 IU/day of heparin everyday for 4 weeks, 4 mg MMC on days 6, 13, 20, 27, and 10 mg CDDP on days 7, 14, 21, 28). The remaining 21 patients were treated without adjuvant therapy during the perioperative period. Results: All patients except one completed the portal infusion chemotherapy without toxicity. The cumulative liver metastasis-free survival rate in the PI4W group was significantly higher than those in the other two groups. Furthermore, in the PI4W group, 3-year survival was 91.6% and 5-year survival was 70.5%, rates which were significantly better than those observed in the other two groups. Conclusion: PI4W therapy after surgery is feasible and could become a promising adjuvant therapy in patients with potentially curative resection of pancreatic cancer.

AB - Aims: We retrospectively assessed the benefits of 5-fluorouracil (5-FU)- and heparin-based portal infusion chemotherapy combined with systemic administration of mitomycin C (MMC) and cisplatin (CDDP) for 4 weeks following surgery (PI4W). The goal was to determine if this treatment prevented liver metastasis and improved survival for patients with potentially curative resection of pancreatic cancer. Methods: 68 patients who underwent pancreatectomy from January 1995 to August 2007 were treated. Of these cases, 22 patients received portal infusion with 5-FU (250 mg/day) for 2 weeks (PI2W) following surgery, while 25 patients received PI4W therapy (250 mg/day of 5-FU with 2,000 IU/day of heparin everyday for 4 weeks, 4 mg MMC on days 6, 13, 20, 27, and 10 mg CDDP on days 7, 14, 21, 28). The remaining 21 patients were treated without adjuvant therapy during the perioperative period. Results: All patients except one completed the portal infusion chemotherapy without toxicity. The cumulative liver metastasis-free survival rate in the PI4W group was significantly higher than those in the other two groups. Furthermore, in the PI4W group, 3-year survival was 91.6% and 5-year survival was 70.5%, rates which were significantly better than those observed in the other two groups. Conclusion: PI4W therapy after surgery is feasible and could become a promising adjuvant therapy in patients with potentially curative resection of pancreatic cancer.

KW - 5-Fluorouracil

KW - Adjuvant therapy

KW - Cisplatin

KW - Curative resection, pancreatic cancer

KW - Heparin-based portal infusion chemotherapy

KW - Mitomycin C

UR - http://www.scopus.com/inward/record.url?scp=77952310481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952310481&partnerID=8YFLogxK

U2 - 10.1159/000244265

DO - 10.1159/000244265

M3 - Article

C2 - 20484963

AN - SCOPUS:77952310481

VL - 10

SP - 250

EP - 258

JO - Pancreatology

JF - Pancreatology

SN - 1424-3903

IS - 2-3

ER -